The global Pediatric Obesity Management Market is anticipated to achieve a valuation of approximately US$ 3.2 billion in 2023, with projections indicating steady growth over the next decade. The market is expected to accumulate a value of US$ 4.74 billion by 2033, registering a compound annual growth rate (CAGR) of 4% during the forecast period from 2023 to 2033. The market recorded a CAGR of 3% during the historical period from 2018 to 2022.
The growth of the Pediatric Obesity Management Market can be attributed to the alarming rise in childhood obesity rates worldwide, which has become a pressing public health concern. Increased awareness among parents, educators, and healthcare providers about the long-term health implications of obesity in children is driving demand for effective management solutions.
Key factors contributing to market expansion include the development of comprehensive obesity management programs, innovative dietary and physical activity interventions, and the rising availability of obesity-related treatments tailored for children. Additionally, governmental and non-governmental initiatives aimed at promoting healthy lifestyles among children are further enhancing the market’s growth potential.
North America currently holds a significant share of the Pediatric Obesity Management Market, driven by high prevalence rates of childhood obesity, advanced healthcare infrastructure, and significant investment in pediatric health programs. The Asia-Pacific region is expected to emerge as a high-growth area due to increasing urbanization, changing dietary habits, and growing healthcare awareness.
As the Pediatric Obesity Management Market continues to evolve, stakeholders are likely to focus on research and development, seeking to introduce innovative solutions that effectively address the unique needs of children facing obesity. The future of the Pediatric Obesity Management Market appears promising, offering opportunities for improved health outcomes and a healthier future for children globally.
2018 to 2022 Pediatric Obesity Management Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider, Future Market Insights- the market for Pediatric Obesity Management reflected a value of 3% during the historical period, 2018 to 2022. During this period, the demand for treatment for Pediatric Obesity increased, driven by factors such as an increase in the prevalence of pediatric obesity, rising awareness about the health risks associated with obesity, and the development of new and innovative treatment options.
Moving forward, it is expected that the pediatric obesity management market will continue to grow. Factors such as increasing government initiatives and funding towards obesity prevention and management programs, rising disposable income, and growing healthcare infrastructure are expected to further boost the growth of the market. Additionally, there is a trend towards developing new and innovative treatment options for pediatric obesity, such as pharmacological treatments and bariatric surgery.
Overall, the demand for pediatric obesity management is expected to increase in the forecast period of 2023 to 2033, driven by a growing need for effective solutions to prevent and manage pediatric obesity. The market is likely to continue to be segmented based on treatment type, with lifestyle modifications remaining the most common treatment option, followed by medications and surgery. However, new and innovative treatment options are expected to continue to emerge, expanding the range of available treatment options for pediatric obesity management.
Furthermore, in the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies are creating awareness of Pediatric Obesity Management, fuelling the market growth. Thus, the market for Pediatric Obesity Management is expected to register a CAGR of 4% in the forecast period 2023 to 2033.
Market Competition
Key players in the market include companies such as Pfizer Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., AstraZeneca, Herbalife Ltd., Apollo Endosurgery, Ethicon, Inc., Takeda Pharmaceutical Company, VIVUS Inc., Currax Pharmaceuticals LLC, along with healthcare providers and technology companies among other global players.
- In June 2021, The USA Food and Drug Administration has granted approval for Wegovy (semaglutide) injection (2.4 mg once weekly) to be used as a treatment for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition, such as high blood pressure, high cholesterol or type 2 diabetes. The drug can be used in combination with a reduced calorie diet and increased physical activity. This under-the-skin injection marks the first approved drug for chronic weight management in adults with obesity or overweight since 2014. It is recommended for patients with a body mass index (BMI) of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater.
Key Companies Profiled
Pfizer Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., AstraZeneca, Herbalife Ltd., Apollo Endosurgery, Ethicon, Inc., Takeda Pharmaceutical Company, VIVUS Inc., Currax Pharmaceuticals LLC
Key Segments Profiled in the Pediatric Obesity Management Industry Survey
Drug Class:
- Lorcaserin
- Liraglutide
- Phentermine
- Setmelanotide
- Others
Route of Administration:
- Oral
- Injectable
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
